Initial assessment of real-world usage of extended-release injectable paliperidone palmitate among medicaid insured schizophrenia patients

Kamat, Siddhesh; Gutiérrez, Benjamín; Eramo, Anna; Zubek, Donna; Baker, Ross A.; Lin, Jingxia; Karson, Craig N.

doi:10.1016/j.jval.2013.03.1580

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients in the AOM 400 group were treated with the 400-mg dose, and those in the PP group were treated with 156- or 234-mg doses. These dosing scenarios align closely with published dosing scenarios seen in clinical trials and real-world treatment [ 16 , 31 , 32 ].…”

Section: Discussionsupporting

confidence: 76%

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Sapin¹,

Hartry

Kamat

et al. 2016

DIC

View full text Add to dashboard Cite

Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable schizophrenia. The present analysis used health economics assessment data collected during the QUALIFY study to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. Compared with those receiving PP, patients receiving AOM 400 incurred significantly lower direct total costs ($8908±186 vs $9675±190, p=0.005) and treatment costs ($7967±113 vs $8706±116, p<0.001). Effectiveness results in the subset of patients included in the cost analyses were similar to the overall population: mean (95% CI) improvement in Heinrichs-Carpenter Quality of Life Scale total score was greater with AOM 400 (5.97 [3.87; 8.08]) compared with PP (2.85 [0.56; 5.08]). Likewise, Clinical Global Impression–Severity improved more in the AOM 400 group (−0.59 [−0.71; −0.47]) compared with PP group (−0.37 [−0.46; −0.27]). Therefore, the analysis of data from stabilized patients with schizophrenia in the QUALIFY study indicated that AOM 400 is associated with lower health-care costs and greater effectiveness compared with PP and thus represents the economically dominant strategy.

show abstract

Section: Discussionsupporting

confidence: 76%

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Sapin¹,

Hartry

Kamat

et al. 2016

DIC

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States

Citrome

Kamat

Sapin

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

AOM consistently provided favorable clinical benefits. Under various dosing scenarios, AOM results indicated fewer relapses at lower overall costs or a reasonable cost-effectiveness threshold (i.e., less than the cost of a hospitalization relapse) vs PLAI. Given the heterogeneous nature of schizophrenia and variability in treatment response, health plans may consider open access for treatments like AOM. Since model inputs were based on data from separate placebo-controlled trials, generalization of results to the real-world setting is limited.

show abstract

Initial assessment of real-world usage of extended-release injectable paliperidone palmitate among medicaid insured schizophrenia patients

Cited by 2 publications

References 0 publications

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States

Contact Info

Product

Resources

About